04:09 AM EDT, 08/12/2026 (MT Newswires) -- ExpreS2ion Biotech Holding (EXPRS2.ST) said Wednesday an independent safety monitoring board found no dose-limiting toxicities in a phase 1 trial of its ES2B-C001 immunotherapy targeting HER2-expressing cancers. The board recommended expanding the highest-dose cohort of 450 micrograms by three patients, booting the safety and immunogenicity dataset ahead of the study's primary readout, expected by the end of 2026. Preliminary data showed anti-HER2 antibody responses in 12 of 13 evaluable patients, including all five who completed the five-dose regimen. The biotechnology company now expects to begin phase 2 testing in the second half of 2027, compared with a previous target of mid-2027, to allow regulatory discussions in Europe and the US.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.